Precision BioSciences, Inc.
NASDAQ:DTILBiotechnology
+$0.11 today
- Market cap
- $198.34M
- Beta
- 1.28
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$3.47
Volume 0.37M
Average 0.31M
DTIL Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Precision BioSciences, Inc.NASDAQ: DTIL
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $640K fell 9.2% year over year, ahead of the -30.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 5.6% from the prior quarter. Over 3 fiscal years it compounded at -32.6% a year.
Context
- Depreciation & amortization amounted to 8.0% of revenue in FY2025, up 1.4 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -9.2% holds above the trailing-twelve-month pace of -30.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 2.75M USD
- Year-over-year change
- -39.9%
- 4-year CAGR
- -27.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.75M | -39.9% |
| FY2024 | 2024-12-31 | 4.58M | -44.6% |
| FY2023 | 2023-12-31 | 8.26M | -8.3% |
| FY2022 | 2022-12-31 | 9M | -11.7% |
| FY2021 | 2021-12-31 | 10.2M | — |
Depreciation & Amortization vs competitors
How DTIL compares with its peers on the latest reported figures
- DTIL's LTM Mar 2026 depreciation & amortization of $2.69M is the 3rd highest of the 7 companies compared; the peer median is $520K.
- Its year-over-year change of -30.3% is the 5th highest of 6, against a peer median of +3.4%.
- Depreciation & amortization amounts to 6.0% of revenue for DTIL, versus a peer median of 1.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $8.8M | +4.8% | +4.5% | 47.8% | |
| LTM Mar 2026 | $2.92M | +23.9% | -7.1% | 1.9% | |
| LTM Mar 2026 | $2.69M | -30.3% | -32.6% | 6.0% | |
| LTM Mar 2026 | $678K | -80.7% | -39.1% | 1.2% | |
| LTM Mar 2026 | $362K | -25.1% | +1.9% | 0.7% | |
| FY2025 | $323K | — | — | 1.7% | |
| LTM Mar 2026 | $185K | +3.4% | +2.9% | — | |
| Peer median (excluding DTIL) | $520K | +3.4% | +1.9% | 1.7% | |
Competitors are the stored peer set for DTIL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 115.53M | 25.1M | 48.73M | 68.7M | 34.26M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.75M |
| Gross Profit | 115.53M | 25.1M | 48.73M | 68.7M | 31.51M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 92.0% |
| Research & Development | 115.24M | 46.12M | 53.38M | 59.56M | 54.17M |
| Selling, General & Admin | 39.67M | 41.28M | 39.09M | 35.3M | 32.24M |
| Operating Expenses | 154.91M | 87.41M | 92.46M | 94.86M | 83.66M |
| Depreciation & Amortization | 10.2M | 9M | 8.26M | 4.58M | 2.75M |
| EBITDA | (20.27M) | (62.79M) | (32.04M) | 13.53M | (42.43M) |
| EBITDA Margin | -17.5% | -250.2% | -65.8% | 19.7% | -123.8% |
| Operating Income | (39.38M) | (62.31M) | (43.74M) | (26.16M) | (52.15M) |
| Operating Margin | -34.1% | -248.3% | -89.8% | -38.1% | -152.2% |
| Interest Income | 208K | 3.47M | 7.69M | 6.76M | 4.24M |
| Interest Expense | 132K | 1.11M | 2.23M | 1.78M | 1.42M |
| Other Income / Expenses | 8.77M | (10.6M) | 1.21M | 33.33M | 5.54M |
| Income Before Tax | (30.6M) | (72.91M) | (42.53M) | 7.17M | (46.61M) |
| Pre-Tax Margin | -26.5% | -290.5% | -87.3% | 10.4% | -136.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (30.6M) | (111.64M) | (61.32M) | 7.17M | (46.61M) |
| Net Margin | -26.5% | -444.8% | -125.8% | 10.4% | -136.0% |
| EPS (Basic) | (15.60) | (38.10) | (15.96) | 1.05 | (3.63) |
| EPS (Diluted) | (15.60) | (38.10) | (15.96) | 1.04 | (3.63) |
| Weighted Avg Shares | 1.96M | 2.93M | 3.84M | 6.83M | 12.83M |
| Weighted Avg Shares (Diluted) | 1.96M | 2.93M | 3.84M | 6.88M | 12.83M |
Precision BioSciences, Inc.
NASDAQ:DTIL
Intrinsic Alpha fair value
Locked
Current Price
$7.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.